Competence network hepatitis (Hep-Net);Kompetenznetz hepatitis (Hep-Net)

Internist

Volumn 45, Issue 4, 2004, Pages 415-421

  Wedemeyer, H ^a   Meyer, S ^a   Manns, M P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Clinical studies; Epidemiology; Hep Net; Hepatitis; Network

Indexed keywords

HEPATITIS C VACCINE;

CHRONIC HEPATITIS; COMPETENCE; CONFERENCE PAPER; DISEASE COURSE; E-MAIL; GERMANY; HEALTH CARE ACCESS; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; TREATMENT INDICATION; VIRUS INFECTIVITY;

BIOMEDICAL RESEARCH; CLINICAL TRIALS; COOPERATIVE BEHAVIOR; GERMANY; GOVERNMENT PROGRAMS; HEPATITIS; HUMANS; INFORMATION DISSEMINATION; INFORMATION STORAGE AND RETRIEVAL; INTERINSTITUTIONAL RELATIONS; INTERNET; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROFESSIONAL COMPETENCE; QUALITY OF HEALTH CARE; REMOTE CONSULTATION; TECHNOLOGY TRANSFER;

EID: 2942582582     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-004-1154-2     Document Type: Conference Paper

References (21)

1. Schreier E, Höhne M (2001) Hepatitis C - Epidemiologie und Prävention. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 44: S54-S61
2. Jilg W, Hottentrager B, Weinberger K et al. (2001) Prevalence of markers of hepatitis B in the adult German population. J Med Virol 63: 96-102
3. Rizzetto M (2000) Hepatitis D: virology, clinical and epidemiological aspects. Acta Gastroenterol Belg 63: 221-224
4. Wedemeyer H, Tillmann HL, Tegtmeyer B et al.(2001) Infection with multiple hepatitis viruses: Evidence for suppression of HCV replication by HDV and HBV. Hepatology 34: 223A
5. Lok AS, Heathcote EJ, Hoofnagle JH (2001) Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 120: 1828-1853
6. Hoofnagle JH (2002) Course and outcome of hepatitis C. Hepatology 36: S21-S29
7. Alberti A, Boccato S, Vario A, Benvegnu L (2002) Therapy of acute hepatitis C. Hepatology 36: S195-S200
8. Jaeckel E, Cornberg M, Wedemeyer H et al. (2001) Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345: 1452-1457
9. Gerlach JT, Diepolder HM, Zachoval R et al. (2003) Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125: 80-88
10. Seeff LB, Hollinger FB, Alter HJ et al. (2001) Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 33: 455-463
11. Seeff LB, Miller RN, Babkin CS et al. (2000) 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 132: 105-111
12. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U (2000) Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 32: 91-96
13. Seeff LB, Hoofnagle JH (2002) National institutes of health consensus development conference: management of hepatitis C 2002. Hepatology 36: 51-52
14. Manns MP, McHutchison JG, Gordon SC et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965
15. Fried MW, Shiffman ML, Reddy KR et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982
16. Hadziyannis S, Cheinguer H, Morgan T et al. (2001) Peg-Interferon alfa-2a (40KD) (PEGASYS®) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double blind, multicentre study examining effect and duration of treatment and RBV dose. J Hepatol 36: 3
17. Kraus MR, Schafer A, Scheurlen M (2001) Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med 345: 375-376
18. Benhamou JP, Hinrichsen H, Sentjens R et al. (2002) Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype-1, with advanced liver fibrosis. Hepatology 36: 304A
19. Hinrichsen H, Benhamou JP, Reiser M et al. (2002) First report on the antiviral efficacy of BILN 2061, a novel HCV serine protease inhibitor, in patients with chronic hepatitis C genotype-1. Hepatology 36: 379A
20. Meyer S, Wedemeyer H (2003) Der angemessene Umgang mit einem Hepatitis C Patienten - Psychologische und soziale Aspekte der Hepatitis C. In: Manns MP, Wedemeyer H (Hrsg) Handbuch Hepatitis C: Natürlicher Verlauf, Diagnose, Therapie. Uni-Med, Bremen
21. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J (2002) Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 35: 704-708